InvestorsHub Logo
Followers 138
Posts 23728
Boards Moderated 0
Alias Born 04/08/2004

Re: Turner2017 post# 281726

Saturday, 11/07/2020 10:51:02 PM

Saturday, November 07, 2020 10:51:02 PM

Post# of 470061

The ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study enrolled 31 patients with Rett syndrome and all patients completed the 7-week trial.


https://www.anavex.com/anavex-life-sciences-announces-completion-of-anavex2-73-blarcamesine-u-s-phase-2-rett-syndrome-clinical-trial/

Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial


http://www.anavex.com/anavex-life-sciences-announces-achievement-of-enrollment-target-for-the-anavex2-73-blarcamesine-phase-2-parkinsons-disease-dementia-pdd-clinical-trial/

GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News